Goldman Sachs
MRNA icon

Goldman Sachs’s Moderna MRNA Stock Holding History

Goldman Sachs’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-14,600
Closed -$431K – 6809
2025
Q4 		$431K Hold
14,600
– – ﹤0.01% 5687
2025
Q3 		$377K Hold
14,600
– – ﹤0.01% 5657
2025
Q2 		$403K Sell
14,600
-109,900
-88% -$2.89M ﹤0.01% 5285
2025
Q1 		$3.53M Buy
124,500
+74,900
+151% +$2.66M ﹤0.01% 3685
2024
Q4 		$2.06M Sell
49,600
-174,700
-78% -$8.35M ﹤0.01% 4255
2024
Q3 		$15M Buy
224,300
+97,800
+77% +$8.98M ﹤0.01% 2319
2024
Q2 		$15M Buy
126,500
+19,000
+18% +$2.4M ﹤0.01% 2120
2024
Q1 		$11.5M Sell
107,500
-66,200
-38% -$6.67M ﹤0.01% 2354
2023
Q4 		$17.3M Buy
173,700
+104,300
+150% +$8.77M ﹤0.01% 2037
2023
Q3 		$7.17M Sell
69,400
-20,600
-23% -$2.3M ﹤0.01% 2670
2023
Q2 		$10.9M Buy
90,000
+3,600
+4% +$480K ﹤0.01% 2362
2023
Q1 		$13.3M Sell
86,400
-181,600
-68% -$30M ﹤0.01% 2167
2022
Q4 		$48.1M Buy
268,000
+146,700
+121% +$24M 0.01% 1203
2022
Q3 		$14.3M Buy
121,300
+81,500
+205% +$12.4M ﹤0.01% 2161
2022
Q2 		$5.68M Sell
39,800
-107,000
-73% -$15.3M ﹤0.01% 3016
2022
Q1 		$25.3M Sell
146,800
-6,400
-4% -$1.08M 0.01% 1858
2021
Q4 		$38.9M Buy
153,200
+17,000
+12% +$4.97M 0.01% 1548
2021
Q3 		$52.4M Buy
136,200
+53,800
+65% +$19.8M 0.01% 1254
2021
Q2 		$19.4M Hold
82,400
– – ﹤0.01% 2071
2021
Q1 		$10.8M Buy
82,400
+45,600
+124% +$6.61M ﹤0.01% 2497
2020
Q4 		$3.84M Buy
36,800
+6,100
+20% +$617K ﹤0.01% 3208
2020
Q3 		$2.17M Buy
+30,700
New +$2.14M ﹤0.01% 3506
2020
Q2 		– Sell
-8,700
Closed -$261K – 5379
2020
Q1 		$261K Buy
+8,700
New +$200K ﹤0.01% 4583
2019
Q4 		– Sell
-19,300
Closed -$307K – 5341
2019
Q3 		$307K Sell
19,300
-67,800
-78% -$1M ﹤0.01% 4676
2019
Q2 		$1.27M Buy
87,100
+17,100
+24% +$367K ﹤0.01% 3821
2019
Q1 		$1.42M Buy
+70,000
New +$1.3M ﹤0.01% 3853

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs's MRNA Position: Q1 2026 in Review

Goldman Sachs increased its Moderna (MRNA) stake by 67% in Q1 2026, buying an estimated $124M and bringing the position to 6,603,697 shares worth $335M. The position accounts for 0.04% of the portfolio, ranked #466.

Goldman Sachs first reported a position in MRNA in Q4 2018 and has held it in 30 quarters since. The position peaked at $610M in Q3 2021. 722 funds tracked by Wall St. Rank hold MRNA as of Q1 2026.

  • Goldman Sachs held 6,603,697 shares of Moderna worth $335M as of Q1 2026.
  • Goldman Sachs bought 2,653,078 Moderna shares in Q1 2026, an estimated $124M.
  • Moderna made up 0.04% of Goldman Sachs's portfolio in Q1 2026, its #466 holding.
  • Goldman Sachs first reported a position in Moderna in Q4 2018 and has held it in 30 quarters since.
  • Goldman Sachs's Moderna position peaked at $610M in Q3 2021.
  • 722 funds tracked by Wall St. Rank held Moderna as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.